Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.69 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.69 |
| ▸ | TAS1R2 | Q8TE23 | 9/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307512 | 0.84 | CYP2C19 (0.56) | TAS1R3TAS1R1TAS1R2CYP2C19HCRTR1 | |
| SCHEMBL702131 | 0.82 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6382294 | 0.80 | TAS1R3 (0.58) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6382289 | 0.80 | TAS1R3 (0.58) | TAS1R3TAS1R1TAS1R2HCRTR1MAPK14 | |
| SCHEMBL6382292 | 0.80 | TAS1R3 (0.58) | TAS1R3TAS1R1TAS1R2HCRTR1MAPK14 | |
| SCHEMBL6382296 | 0.80 | TAS1R3 (0.58) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5950297 | 0.79 | TAS1R3 (0.51) | TAS1R3TAS1R1TAS1R2CYP2C19TSHR | |
| SCHEMBL4990886 | 0.78 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2RAB9ATYK2 | |
| SCHEMBL5032040 | 0.78 | SSTR3 (0.52) | RAB9AMEN1KMT2ASSTR3HTT | |
| SCHEMBL1756678 | 0.78 | SSTR3 (0.52) | RAB9AMEN1KMT2ASSTR3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| EP-1940792-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-1 AND/OR PIM-3 | Exelixis, Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007044724-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-I AND/OR PIM-3 | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| EP-1940792-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-1 AND/OR PIM-3 | Exelixis, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007044724-A2 | AMINOPYRIMIDINE, AMINOPYRIDINE AND ANILINE DERIVATIVES INHIBITORS OF PIM-I AND/OR PIM-3 | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | TAS1R3 993/4885TAS1R1 1244/4885TAS1R2 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.